No Data
Remegen (9995.HK): Commercialization slightly exceeds expectations, focusing on the value of the late-stage pipeline.
Investment Highlights: [Maintain a "shareholding" rating. In 2024 Q3, revenue reached 0.47 billion yuan (+34.6%), with a net loss of 0.29 billion yuan (a decrease of 0.04 billion yuan compared to the same period last year), slightly exceeding expectations. Thanks to product manufacturing.
Remegen (688331): Good income growth, core products expected to continuously expand into new indications.
Revenue in 1-3Q24 meets our expectations, while the loss exceeds expectations. The company announced its 1-3Q24 performance: revenue of 1.21 billion yuan, up by 57.1% year-on-year; net income attributable to shareholders was -1.07 billion yuan, corresponding to a loss per share of -1.99 yuan.
REMEGEN(9995.HK):STRONG SALES IN Q3 WITH A NARROWED NET LOSS
The Hong Kong stock sector generally fell with trading volume increasing to 160 billion Hong Kong dollars. Institutions believe that the Hang Seng Index at 19,500 points is worth absorbing.
Produced jointly by Zhongtai International and CaiLian News.
REMEGEN CO. LTD.(09995.HK):CONTINUOUS IMPROVEMENT OF FINANCIAL PERFORMANCE
Hong Kong Stock Market Moves | Remegen (09995) rose by more than 10%, with a significant increase in the company's main business income. The third-quarter loss narrowed by more than 30% compared to the previous quarter.
Remegen (09995) rose more than 10%, as of the time of publication, increased by 10.8%, to 16 Hong Kong dollars, with a turnover of 78.6233 million Hong Kong dollars.
No Data
No Data